Pyxis Oncology, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period
Pyxis Oncology, Inc. (PYXS) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period of 1.09 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod · last filed 2026-08-13
- Pyxis Oncology, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2025-12-31 was 99.52K shares.
- Pyxis Oncology, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2025-09-30 was 196.86K shares, a 138.56% increase year-over-year.
- Pyxis Oncology, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2024-12-31 was 0.00 shares, a 100.00% decline year-over-year.
- Pyxis Oncology, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2024-09-30 was 82.52K shares, a 63.21% decline year-over-year.
- Pyxis Oncology, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2025 was 629.65K shares, a 122.55% increase from fiscal 2024.
- Pyxis Oncology, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2024 was 282.93K shares, a 60.79% decline from fiscal 2023.
- Pyxis Oncology, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2023 was 721.60K shares, a 51.31% increase from fiscal 2022.
- Pyxis Oncology, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2022 was 476.90K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 1.09K shares 10-Q · filed 2026-08-13 | |||
| 2025-12-31 | 99.52K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | 296.38K shares derived: sum of 2 quarters · filed 2026-03-23 | 629.65K shares 10-K · filed 2026-03-23 | |
| 2025-09-30 | 196.86K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | 530.13K shares 10-Q · filed 2025-11-03 | ||
| 2025-06-30 | 333.27K shares 10-Q · filed 2025-08-14 | |||
| 2024-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | 82.52K shares derived: sum of 2 quarters · filed 2025-03-18 | 102.06K shares derived: sum of 3 quarters · filed 2025-03-18 | 282.93K shares 10-K · filed 2025-03-18 |
| 2024-09-30 | 82.52K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | 102.06K shares derived: sum of 2 quarters · filed 2024-11-12 | 282.93K shares 10-Q · filed 2024-11-12 | 699.05K shares derived: sum of 4 quarters · filed 2024-11-12 |
| 2024-06-30 | 19.53K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | 200.41K shares 10-Q · filed 2024-08-14 | 616.53K shares derived: sum of 3 quarters · filed 2024-08-14 | 840.85K shares derived: sum of 4 quarters · filed 2024-08-14 |
| 2024-03-31 | 180.87K shares 10-Q · filed 2024-05-14 | 596.99K shares derived: sum of 2 quarters · filed 2024-05-14 | 821.32K shares derived: sum of 3 quarters · filed 2024-05-14 | 821.32K shares derived: sum of 4 quarters · filed 2024-05-14 |
| 2023-12-31 | 416.12K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | 640.45K shares derived: sum of 2 quarters · filed 2024-03-21 | 640.45K shares derived: sum of 3 quarters · filed 2024-03-21 | 721.60K shares 10-K · filed 2024-03-21 |
| 2023-09-30 | 224.33K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | 224.33K shares derived: sum of 2 quarters · filed 2023-11-07 | 305.48K shares 10-Q · filed 2023-11-07 | 373.83K shares derived: sum of 4 quarters · filed 2023-11-07 |
| 2023-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | 81.15K shares 10-Q · filed 2023-08-11 | 149.50K shares derived: sum of 3 quarters · filed 2023-08-11 | 524.21K shares derived: sum of 4 quarters · filed 2023-08-11 |
| 2023-03-31 | 81.15K shares 10-Q · filed 2023-05-11 | 149.50K shares derived: sum of 2 quarters · filed 2023-05-11 | 524.21K shares derived: sum of 3 quarters · filed 2023-05-11 | |
| 2022-12-31 | 68.35K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | 443.06K shares derived: sum of 2 quarters · filed 2023-03-22 | 476.90K shares 10-K · filed 2023-03-22 | |
| 2022-09-30 | 374.71K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01 | 408.55K shares 10-Q · filed 2022-11-01 | ||
| 2022-06-30 | 33.84K shares 10-Q · filed 2022-08-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |